<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37442375</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Long COVID: Potential role of the Reactive Species Interactome.</ArticleTitle><Pagination><StartPage>280</StartPage><EndPage>281</EndPage><MedlinePgn>280-281</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2023.07.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(23)00376-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feelisch</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and NIHR Biomedical Research Center, University Hospital Southampton, NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK. Electronic address: m.feelisch@soton.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Anna D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and NIHR Biomedical Research Center, University Hospital Southampton, NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cumpstey</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and NIHR Biomedical Research Center, University Hospital Southampton, NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santolini</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ Paris-Sud, Universit&#xe9; Paris-Saclay, F-91198 Gif-sur-Yvette Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Alan A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Institute of Human Nutrition, University of Southampton and University Hospital Southampton, Tremona Road, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Infect. 2022 Feb;84(2):158-170. doi: 10.1016/j.jinf.2021.11.011</RefSource><PMID Version="1">34813820</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest MF wishes to disclose that in the past 36 months he has received research grant support from the Bill &amp; Melinda Gates Foundation for COV-Surf, a study on the use of nebulized surfactant for the treatment of severe COVID-19 in adults, and the UK National Institute of Health and Care Research for MedROX, a study on oxidative stress, redox status and surfactant metabolism in mechanically-ventilated patients receiving different approaches to oxygen therapy, and has served as a consultant for ASEA. All other authors declare no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37442375</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2023.07.004</ArticleId><ArticleId IdType="pii">S0163-4453(23)00376-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>